Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 10, Number 8—August 2004

Research

Antimicrobial Drug Use and Methicillin-resistant Staphylococcus aureus, Aberdeen, 1996–2000

Dominique L. Monnet*, Fiona M. MacKenzie†Comments to Author , José María López-Lozano‡, Arielle Beyaert§, Máximo Camacho§, Rachel Wilson†, David Stuart†, and Ian M. Gould†
Author affiliations: *Statens Serum Institut, Copenhagen, Denmark; †Aberdeen Royal Infirmary, Aberdeen, Scotland; ‡Hospital Vega Baja, Orihuela (Alicante), Spain; §University of Murcia, Murcia, Spain

Main Article

Figure 3

Evolution of the monthly % methicillin-resistant Staphylococcus aureus (MRSA) and monthly sum of lagged antimicrobial use as identified in polynomial distributed lag (PDL) model: macrolides (lags of 1 to 3 months), third-generation cephalosporins (lags of 4 to 7 months), and fluoroquinolones (lags of 4 and 5 months), Aberdeen Royal Infirmary, January 1996–December 2000.

Figure 3. Evolution of the monthly % methicillin-resistant Staphylococcus aureus (MRSA) and monthly sum of lagged antimicrobial use as identified in polynomial distributed lag (PDL) model: macrolides (lags of 1 to 3 months), third-generation cephalosporins (lags of 4 to 7 months), and fluoroquinolones (lags of 4 and 5 months), Aberdeen Royal Infirmary, January 1996–December 2000.

Main Article

TOP